

1 Immunogenicity and efficacy of the COVID-19 candidate vector
2 vaccine MVA SARS 2 S in preclinical vaccination

3

4 Alina Tscherne^{1,3*}, Jan Hendrik Schwarz^{1*}, Cornelius Rohde^{2,4*}, Alexandra Kupke^{2,4*}, Georgia
5 Kalodimou^{1,3*}, Leonard Limpinsel¹, Nisreen M.A. Okba⁵, Berislav Bošnjak⁶, Inga Sandrock⁶,
6 Sandro Halwe^{2,4}, Lucie Sauerhering^{2,4}, Katrin Brosinski¹, Nan Liangliang¹, Elke Duell^{1,3}, Sylvia
7 Jany¹, Astrid Freudenstein¹, Jörg Schmidt^{2,4}, Anke Werner^{2,4}, Michelle Gellhorn Sera^{2,4}, Michael
8 Klüver^{2,4}, Wolfgang Guggemos⁹, Michael Seilmaier⁹, Clemens-Martin Wendtner⁹, Reinhold
9 Förster^{6,7,8}, Bart L. Haagmans⁵, Stephan Becker^{2,4}, Gerd Sutter^{1,3}, Asisa Volz^{1,3,10}

10 ¹Division of Virology, Department of Veterinary Sciences, LMU Munich, Munich, Germany

11 ²Institute of Virology, Philipps University Marburg, Marburg, Germany

12 ³German Center for Infection Research, Munich, Germany

13 ⁴German Center for Infection Research, Gießen-Marburg-Langen, Germany

14 ⁵Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands

15 ⁶Institute of Immunology, Hannover Medical School, Hannover, Germany

16 ⁷German Center for Infection Research, Hannover, Germany

17 ⁸Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany

18 ⁹Munich Clinic Schwabing, Academic Teaching Hospital, LMU Munich, Munich, Germany

19 ¹⁰Institute of Virology, University of Veterinary Medicine Hannover, Germany

20 * These authors contributed equally to this work

21 **Corresponding author:** Gerd Sutter, Division of Virology, Department of Veterinary Sciences,

22 LMU Munich, Veterinärstr.13, 80539 Munich, Germany, phone +4989 21802514,

23 Email: gerd.sutter@lmu.de

24 **Author Contributions:**

25 AV and GS conceptualized the work, designed vaccine and study, and reviewed all data. AT,
26 JHS, GK, LL, NL, ED, SJ, and AF constructed, prepared and characterized vaccine, and
27 performed the in vitro and in vivo experiments for preclinical safety and immunogenicity, aided by
28 KB the pathology. SB, CR, AK, SH, JS, AW, MGS, MK established in vivo SARS-CoV-2 infection
29 model and performed in vitro and in vivo experiments to characterize safety, immunogenicity and
30 efficacy. BLH, NMAO together with RF, BB, IS performed virologic and immunologic assays to
31 characterize immunogenicity. CMW, WG, MS provided and analyzed patient sera. AV, AT, JHS,
32 GK and GS wrote manuscript together with all co-authors.

33

34 **Competing Interest Statement:** The authors declare no competing interests.

35

36 **Classification:** Biological Sciences, Microbiology.

37

38 **Keywords:** vaccine vector, vaccinia virus, poxvirus, non-clinical testing

39

40

41

42

43 **Abstract**

44 The severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged as
45 the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with dramatic
46 consequences for global human health and economics. Previously, we reached clinical evaluation
47 with our vector vaccine based on vaccinia virus MVA against the Middle East respiratory
48 syndrome coronavirus (MERS-CoV), which causes an infection in humans similar to SARS and
49 COVID-19. Here, we describe the construction and preclinical characterization of a recombinant
50 MVA expressing full-length SARS-CoV-2 spike (S) protein (MVA-SARS-2-S). Genetic stability
51 and growth characteristics of MVA-SARS-2-S, plus its robust synthesis of S antigen, make it a
52 suitable candidate vaccine for industrial scale production. Vaccinated mice produced S antigen-
53 specific CD8⁺ T cells and serum antibodies binding to S glycoprotein that neutralized SARS-
54 CoV-2. Prime-boost vaccination with MVA-SARS-2-S protected mice sensitized with a human
55 ACE2-expressing adenovirus from SARS-CoV-2 infection. MVA-SARS-2-S is currently being
56 investigated in a phase I clinical trial as aspirant for developing a safe and efficacious vaccine
57 against COVID-19.

58

59

60 **Significance Statement**

61 The highly attenuated vaccinia virus MVA is licensed as smallpox vaccine, and as vector it is a
62 component of the approved Adenovirus-MVA-based prime-boost vaccine against Ebola virus
63 disease. Here we provide results from testing the COVID-19 candidate vaccine MVA-SARS-2-S,
64 a poxvirus-based vector vaccine that proceeded to clinical evaluation. When administered by
65 intramuscular inoculation, MVA-SARS-2-S expresses and safely delivers the full-length SARS-
66 CoV-2 spike (S) protein, inducing balanced SARS-CoV-2-specific cellular and humoral immunity,
67 and protective efficacy in vaccinated mice. Substantial clinical experience has already been
68 gained with MVA vectors using homologous and heterologous prime-boost applications, including
69 the immunization of children and immunocompromised individuals. Thus, MVA-SARS-2-S
70 represents an important resource for developing further optimized COVID-19 vaccines.
71

72

73 **Introduction**

74

75 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of
76 coronavirus disease 2019 (COVID-19), first emerged in late 2019 in China (1). SARS-CoV-2
77 exhibits extremely efficient human-to-human transmission, the new pathogen rapidly spread
78 worldwide, and within months caused a global pandemic, changing daily life for billions of people.
79 The COVID-19 case fatality rate of ~2-5% makes the development of countermeasures a global
80 priority. In fact, the development of COVID-19 vaccine candidates is advancing at an international
81 level with unprecedented speed. About a year after the first known cases of COVID-19 we can
82 account for >50 SARS-Cov-2-specific vaccines in clinical evaluations and >10 candidate vaccines
83 already in phase III trials (2-4). Yet, we still lack information on the key immune mechanisms
84 needed for protection against COVID-19. A better understanding of the types of immune response
85 elicited upon natural SARS-CoV-2 infections has become an essential component to assess the
86 promise of various vaccination strategies (5).

87 The SARS-CoV-2 spike (S) protein serves as the most important target antigen for vaccine
88 development based on preclinical research on candidate vaccines against SARS-CoV or MERS-
89 CoV. The trimeric S glycoprotein is a prominent structure at the virion surface and essential for
90 SARS-CoV-2 cell entry. As a class I viral fusion protein, it mediates virus interaction with the cellular
91 receptor angiotensin-converting enzyme 2 (ACE2), and fusion with the host cell membrane, both
92 key steps in infection. Thus infection can be prevented by S-specific antibodies neutralizing the
93 virus (6-9).

94 Among the front-runner vaccines are new technologies such as messenger RNA (mRNA)-based
95 vaccines and non-replicating adenovirus vector vaccines (10). First reports from these SARS-CoV-
96 2 S-specific vaccines in phase 1/2 clinical studies show acceptable safety and promising

97 immunogenicity profiles, and by now first data from large phase 3 clinical trials show promising
98 levels of protective efficacy (4, 11-13). This is good news because efficacious vaccines will provide
99 a strategy to change SARS-CoV-2 transmission dynamics. In addition, multiple vaccine types will
100 be advantageous to meet specific demands across different target populations. This includes the
101 possibility of using heterologous immunization strategies depending on an individual's health
102 status, boosting capacities and the need for balanced humoral and Th1-directed cellular immune
103 responses.

104 Modified Vaccinia virus Ankara (MVA), a highly attenuated strain of vaccinia virus originating from
105 growth selection on chicken embryo tissue cultures, shows a characteristic replication defect in
106 mammalian cells but allows unimpaired production of heterologous proteins (14). At present, MVA
107 serves as an advanced vaccine technology platform for developing new vector vaccines against
108 infectious disease and cancer including emerging viruses (15). In response to the ongoing
109 pandemic, the MVA vector vaccine platform allows rapid generation of experimental SARS-CoV-2-
110 specific vaccines (16). Previous work from our laboratory addressed the development of an MVA
111 candidate vaccine against MERS with immunizations in animal models demonstrating the safety,
112 immunogenicity and protective efficacy of MVA-induced MERS-CoV S-antigen specific immunity
113 (17-20). Clinical safety and immunogenicity of the MVA-MERS-S candidate vaccine was
114 established in a first-in-man phase I clinical study under funding from the German Center for
115 Infection Research (DZIF) (21).

116 Here, we show that a recombinant MVA virus produces the full-length S protein of SARS CoV-2 as
117 ~190-200 kDa N-glycosylated protein. Our studies confirmed cleavage of the mature full-length S
118 glycoprotein into an amino-terminal domain (S1) and a ~80-100 kDa carboxy-terminal domain (S2)
119 that is anchored to the membrane. When tested as a vaccine in BALB/c mice, recombinant MVA
120 expressing the S glycoprotein induced SARS-CoV-2-specific T cells and antibodies, and robustly
121 protected vaccinated animals against lung infection upon SARS-CoV-2 challenge.

122

123 **Results**

124

125 **Design and generation of candidate MVA vector viruses.** cDNA containing the entire gene
126 sequence encoding SARS-CoV-2 S (SARS-2-S) from the virus isolate Wuhan HU-1 (GenBank
127 accession no. MN908947.1) was placed under the transcriptional control of the enhanced synthetic
128 vaccinia virus early/late promoter PmH5 (22) in the MVA vector plasmid pIIH5red-SARS-2-S, and
129 introduced by homologous recombination into deletion site III in the MVA genome (Fig. 1A). Clonal
130 recombinant MVA viruses expressing SARS-2-S (MVA-SARS-2-S) were isolated in repetitive
131 plaque purification using transient coproduction of the fluorescent marker protein mCherry to
132 screen for red fluorescent cell foci (17, 23). PCR analysis of viral DNA confirmed the genetic
133 integrity of the recombinant viruses demonstrating the site-specific insertion of the heterologous
134 SARS-2-S gene sequences in the MVA genome, and subsequently the proper removal of the
135 mCherry marker gene from the genome of final recombinant viruses (Fig. 1B). MVA-SARS-2-S
136 virus isolates were genetically stable and showed the expected MVA-specific genetics with regard
137 to characteristic deletions and sequence alterations in the MVA genome (*SI Appendix*, Fig. S1).
138 The recombinant viruses replicated efficiently in the chicken embryo fibroblast cell line DF-1, but
139 not in the human cell lines HeLa, A549 or HaCat (Fig. 1C).

140 **Characterization of SARS-CoV-2 S expressed by recombinant MVA.** To determine the
141 expression pattern of the recombinant SARS-CoV-2 S protein, we stained MVA-SARS-2-S infected
142 Vero cells with HAtag or S-specific monoclonal antibodies and analyzed them using fluorescence
143 microscopy. A mouse monoclonal antibody directed against the nine amino acid-HA-tag at the
144 carboxyl (C)-terminus of the recombinant SARS-2-S protein revealed highly specific staining in
145 permeabilized cells corresponding to the expected intracellular localization of the S protein C-
146 terminal end. A SARS-CoV-1 S-specific monoclonal antibody recognizing an epitope in the external
147 domain of the S protein also allowed the specific staining of non-permeabilized MVA-SARS-2-S
148 infected Vero cells, suggesting that the SARS-2-S protein was readily translocated to the
149 cytoplasmic membrane (Fig. 2A).

150 To examine the MVA-produced recombinant S glycoprotein in more detail, we prepared total
151 lysates from MVA-SARS-2-S infected CEF or Vero cells for separation by SDS-PAGE and
152 subsequent immunoblot analysis (Fig. 2). The mouse monoclonal antibody directed against the
153 HAtag at the C-terminus of the recombinant SARS-2-S protein revealed two prominent protein
154 bands that migrated with molecular masses of approximately 190 kDa and 90-100 kDa (Fig 2B).
155 As in the SDS-PAGE the detected protein bands migrated at molecular masses significantly higher
156 than the 145 kDa predicted for full-length SARS-CoV-2 S protein based on its amino acid sequence,
157 we hypothesized that the proteins might be glycosylated. Indeed, NetNGlyc 1.0 server analysis
158 indicated the presence of at least 17 N-glycosylation sites for co- and post-translational
159 modifications. The treatment of cell lysates with peptide-N-glycosidase F (PNGase F), which
160 removes all N-linked oligosaccharide chains from glycoproteins, reduced the molecular masses of
161 the recombinant SARS-2-S protein bands from 190 kDa to 145 kDa and from 90-100 kDa to 65 kDa,
162 matching the expected sizes of unmodified SARS-CoV-2 S and the S2 cleavage product,
163 respectively (Fig 2C).

164 Interestingly, the S2 cleavage band was more prominent in the lysates from infected CEF cells,
165 whereas lysates from infected Vero cells contained more full-length protein, suggesting host cell-
166 specific differences in the proteolytic cleavage of the S protein (Fig. 2B). More importantly, both
167 isoforms were detectable as early as 2 hours post-infection (hpi), indicating proper early
168 transcription from the synthetic MVA promoter PmH5, and their amount increased up to 24 hpi,
169 consistent with the timing of abundant vaccinia viral late protein synthesis (Fig. 2C). Moreover,
170 Western blot analysis using serum antibodies from a COVID-19 patient hospitalized with
171 pneumonia also revealed protein bands corresponding to the molecular masses of full-length S
172 protein or the S2 polypeptide (Fig. 2D).

173 **MVA-SARS-2-S induced antibody responses in mice.** To evaluate whether MVA-SARS-CoV-2
174 induces SARS-CoV-2 specific antibodies, we vaccinated BALB/c mice with a low-dose (LD) or high-
175 dose (HD) of MVA-SARS-CoV-2 (10^7 or 10^8 plaque-forming units (PFU), respectively) using

176 intramuscular (i.m.) administration and prime-boost immunization schedules with a 3-week interval
177 (Fig. 3, *SI Appendix*, Fig. S2). At day 18 after the prime inoculation, we detected serum IgG
178 antibodies binding to whole recombinant SARS-CoV-2 S protein in the sera from 3/8 LD-vaccinated
179 and 4/6 HD-vaccinated animals by ELISA (Fig. 3A). Following the booster immunization on day 21,
180 all vaccinated animals mounted high levels of S-binding serum IgG antibodies with mean titers of
181 1:900 for the LD vaccination group and 1:1257 for the HD group (Fig. 3A). More importantly, sera
182 from vaccinated mice also contained antibodies binding to the S protein receptor-binding domain
183 (RBD). Already at day 18 post priming, the RBD-binding antibodies were detected in 33% of the
184 mice in the LD dose group (2/6 mice, mean OD value 0.35) and 50% of the mice receiving the HD
185 immunization (3/6, mean OD 0.63). The boost vaccinations increased the levels of RBD specific
186 antibodies with 87.5% seropositive mice in the 10^7 dose group (7/8, mean OD 1.81) and 100% of
187 the animals vaccinated with 10^8 PFU MVA-SARS2-S (8/8, mean OD 2.92) (Figure 3B). Since live
188 virus neutralization is the gold standard for coronavirus serologic analysis, we next assessed the
189 mouse sera in two different assays for SARS-CoV-2 neutralization, a plaque reduction
190 neutralization test 50 (PRNT₅₀) (24) and a complete virus neutralization test (VNT₁₀₀) (9) (Fig. 3 C
191 and D). On day 18 following prime immunization the PRNT₅₀ revealed low amounts of SARS-CoV-
192 2 neutralizing antibodies in 50-80% of the sera from vaccinated animals (PRNT₅₀ titres of 20-40 for
193 both dose groups). After the boost vaccinations we detected neutralizing activities in all sera from
194 MVA-SARS-2-S vaccinated mice with average PRNT₅₀ titres of 117 (LD) and 600 (HD) (Fig. 3C).
195 Using the VNT₁₀₀ assay we detected neutralizing activities in 79% of all sera following MVA-SARS-
196 2-S booster immunizations with mean reciprocal titres of 19.8 (4/6 seropositive mice, LD group)
197 and 105.8 (7/8 mice, HD group) (Fig. 3D). We obtained similar results when testing the sera in a
198 recently established high-throughput surrogate virus neutralization test for SARS CoV-2
199 (sVNT)(25) . After the boost immunizations on day 21, we detected levels of surrogate neutralizing
200 antibodies with mean titers of 400 (4/6 seropositive mice, LD) and 840 (6/6, HD) (Fig. 3E, *SI*
201 *Appendix*, Fig. S3). Altogether, these results indicate that both LD and HD 3-week prime-boost

202 immunization protocols induce a robust anti-SARS-CoV2-S humoral response and lead to
203 generation of neutralizing anti-SARS-CoV2-S antibodies.

204 **MVA-SARS-2-S induced T cell responses in mice.** To assess the activation of SARS-CoV-2-
205 specific cellular immunity, we monitored S-specific CD8⁺ and CD4⁺ T cells in BALB/c mice
206 vaccinated with LD or HD MVA-SARS-2-S in prime and prime-boost immunization schedules using
207 3-week intervals (*SI Appendix*, Fig. S2). To assess S antigen-specific T cells by IFN- γ ELISPOT,
208 we isolated splenocytes at day 8 after MVA-SARS-2-S prime or boost immunization and used S-
209 specific peptide stimulation for activation upon *in vitro* culture. Since information is limited on
210 antigen specificities of SARS-CoV-2-specific T cells, we screened the Immune Epitope Database
211 (IEDB) to select putative S-specific peptide epitopes compatible with activation of CD8⁺ or CD4⁺
212 T cells (*SI Appendix*, Tables S1 and S2). When testing pools of the predicted peptides with
213 splenocytes from BALB/c mice immunized with 10⁸ PFU MVA-SARS-2-S, we detected responses
214 above background in several peptide pools and identified the immunodominant SARS-CoV-2 S H2-
215 K^d epitope S₂₆₉₋₂₇₈ (GYLQPRTFL; S1 N-terminal domain, *SI Appendix*, Fig. S4). To evaluate the
216 primary activation of SARS-2-S epitope specific CD8⁺ T cells, we inoculated BALB/c mice once
217 with LD or HD MVA-SARS-2 and analyzed splenocytes on day 8 after vaccination. Single
218 intramuscular immunizations with MVA-SARS-2-S already induced substantial levels of S₂₆₉₋₂₇₈
219 epitope-specific activated CD8⁺ T cells with mean numbers of 341 IFN- γ spot forming cells (SFC)
220 in 10⁶ splenocytes for LD and 275 SFC for HD compared to control mice immunized with non-
221 recombinant MVA (no SFC detectable) (Fig. 4A). ELISPOT data aligned well with FACS analysis
222 of T cells intracellularly stained for IFN- γ , where we also found higher frequencies (means of 0.32-
223 0.36%) and higher absolute numbers of IFN- γ ⁺ CD8⁺ T cells in splenocytes from vaccinated
224 animals compared to control mice (Fig. 4B). Substantial numbers of the activated IFN- γ ⁺ CD8⁺ T
225 cells also co-expressed TNF- α (means of 0.22% and 0.27% of TNF- α expressing cells from total
226 IFN- γ ⁺ expressing cells) (Fig. 4C). Of note, the magnitude of SARS-2-S-specific CD8⁺ T cells did
227 not significantly differ when comparing the groups of mice immunized with LD or HD of MVA-SARS-
228 2-S.

229 The booster immunizations on day 21 further increased the magnitudes of S-specific CD8+ T cells
230 in response to MVA-SARS-2-S vaccination. At day 8 post boost, ELISPOT analysis revealed
231 means of 1,020 IFN- γ SFC in LD vaccinated mice and 1,159 IFN- γ SFC in animals receiving HD
232 MVA-SARS-2-S (Fig. 4D). Intracellular FACS analysis identified frequencies of 0.62% or 0.60%
233 and absolute numbers of 40,873 or 49,553 IFN- γ + CD8+ T cells for mice immunized with LD or HD
234 MVA-SARS-2-S (Fig. 4E). Again, we confirmed that the majority (~75%) of IFN- γ + CD8+ T cells
235 also expressed TNF- α (Fig. 4F). The MVA-specific immunodominant CD8+ T cell determinant
236 F2(G)₂₆₋₃₄ (SPGAAGYDL(26)) served as a control peptide for the detection and comparative
237 analysis of MVA vector-specific CD8+ T cells in BALB/c mice (*SI Appendix*, Fig. S5 and Fig. S6).
238 In addition, using SARS-2-S derived peptides with predicted capacity for MHC II binding we also
239 monitored the presence of activated CD4+ T cells. Using three different peptide pools (*SI Appendix*,
240 Table S2), we confirmed the presence of spike-specific CD4+ T cells in the spleens of mice
241 immunized with LD and HD prime-boost regimens (*SI Appendix*, Fig. S7).

242 **Protective capacity of MVA-SARS-2-S upon SARS-CoV-2 challenge.** To model productive
243 infection with SARS-CoV-2, we used an adenoviral transduction-based mouse model similar to
244 those described recently (27, 28). We intratracheally transduced MVA-SARS-2-S vaccinated
245 BALB/c mice with 5×10^8 PFU of an adenoviral vector encoding both the human ACE2 receptor and
246 the marker protein mCherry (ViraQuest Inc., North Liberty, IA, USA) at about two weeks after prime-
247 boost immunization. Three days later the animals were infected with 1.5×10^4 tissue culture
248 infectious dose 50 (TCID₅₀) SARS-CoV-2 (isolate BavPat1/2020 isolate, European Virus Archive
249 Global # 026V-03883), and four days post challenge the animals were sacrificed, blood samples
250 taken, and the lungs harvested to measure viral loads. Substantial virus RNA loads, on average
251 $>1,000$ SARS-CoV-2 genome equivalents/ng of total RNA, were found in mock-immunized control
252 mice. In contrast, the lung tissue of both LD and HD MVA-SARS-2-S-immunized animals contained
253 significantly lower levels of SARS-CoV-2 RNA (<100 genome equivalents/ng total RNA; Fig. 5A).
254 Adenoviral vector transduction levels of lung tissues were analyzed by real-time RT-PCR analysis
255 to confirm comparable amounts of mCherry RNA (Fig. 5B). In addition, we found easily detectable

256 levels of infectious SARS-CoV-2 (>1000 TCID₅₀/ml) in the lungs from control but not in the tissues
257 of immunized mice indicating the efficient inhibition of SARS-CoV-2 replication by vaccine-induced
258 immune responses (Fig. 5C). In agreement with these data, only sera from MVA-SARS-2-S
259 vaccinated animals (10/11) contained SARS-CoV-2 neutralizing circulating antibodies (Fig. 5D).

260

261 **Discussion**

262

263 Here, we report that the COVID-19 candidate vaccine MVA-SARS-2-S is compatible with clinical
264 use and industrial-scale production. Building on extensive prior experience developing a candidate
265 vaccine against MERS (17-19, 21), we selected the full-length SARS-CoV-2 S protein for delivery
266 by recombinant MVA. The vector virus replicated efficiently in DF-1 cells, the cell substrate for an
267 optimized manufacturing process, and MVA-SARS-2-S stably produces S glycoprotein antigen
268 upon serial amplifications at low multiplicities of infection.

269

270 Similar to our experience gained with MVA-MERS-S, expression of the SARS-CoV-2 S gene by
271 recombinant MVA resulted in a glycoprotein migrating at a molecular mass of about 190 kDa.
272 Treatment with glycosidase to remove all N-linked carbohydrates produced a polypeptide of
273 145 kDa, closely corresponding to the molecular weight predicted from S gene nucleotide
274 sequence. In addition, we observed S1 and S2 cleavage of the full-length SARS-2 S polypeptide,
275 apparently with various efficiencies of proteolytic processing depending on the cell substrate of
276 protein production. This finding is in agreement with previous reports suggesting complex activation
277 of the betacoronavirus S glycoproteins, including the involvement of multiple cleavage events and
278 several host proteases (29, 30). Similar to our findings with the MVA-produced MERS-CoV S
279 protein, SARS-CoV-2 S-specific detection by immunofluorescence included strong surface staining
280 of MVA-SARS-2-S infected cells. We conclude that the recombinant SARS-CoV-2 S protein is
281 trafficking through the Golgi apparatus and is expressed at the cell surface, as shown previously
282 for functional S produced from plasmid expression vectors (7, 31, 32).

283

284 Since the biochemical characterization of the MVA-expressed S suggested production of a mature
285 and properly folded spike antigen, we investigated whether MVA-SARS-2-S elicits S-specific
286 immune responses. In proof-of-principle experiments, mice receiving the MVA-SARS-2-S vaccine
287 twice intramuscularly developed circulating S-specific antibodies that neutralized SARS-CoV-2
288 infections in cell culture and mounted high levels of SARS-2-S-specific CD8⁺ T cells. MVA-SARS-
289 2-S elicited levels of virus neutralizing antibodies in BALB/c mice that were comparable to those
290 induced by ChAdOx1nCoV-19 or MVA-MERS-S vaccinations (18, 33) and evidence from
291 preclinical studies in non-human primates and hamsters indicate that vaccine-induced SARS-CoV-
292 2 neutralizing antibodies correlate with protection against lung infection and clinical disease (34-
293 36). The humoral immune responses elicited by MVA-SARS-2-S and measured by ELISA, two
294 different SARS-CoV-2 neutralization assays and a surrogate neutralization assay pointed to a clear
295 benefit of a booster immunization. These data are in line with results from phase 1 clinical testing
296 of our MVA-MERS-S candidate vaccine providing evidence of humoral immunogenicity using
297 homologous prime-boost vaccination (21). For SARS-CoV-2 neutralizing antibodies we found a
298 strong correlation between the results obtained from authentic virus neutralization (PRNT₅₀,
299 VNT₁₀₀) and the data from surrogate neutralization (sVNT). These data corroborate the findings of
300 a recent study comparing this high-throughput sVNT assay to a pseudotyped virus neutralization
301 assay based on SARS-CoV-2 S protein-carrying vesicular stomatitis virus (25).

302 The i.m. immunizations of BALB/c mice with low and high-dose MVA-SARS-2-S induced robust
303 and nearly equal amounts of SARS-S-specific CD8⁺ T cells in prime and prime-boost vaccination.
304 The average number of S-specific T cells was comparable to the average number of MVA vector-
305 specific T cells highlighting the strong immunogenicity of MVA-SARS-2-S for inducing a SARS-S-
306 specific CD8⁺ T cell response. The importance of vaccine induced T cell responses is illustrated
307 by studies not only monitoring the adaptive immunity to SARS-CoV-2 in patients, but also
308 demonstrating that strong SARS-CoV-2-specific CD4⁺ or CD8⁺ T cell responses are associated
309 with low disease severity in individuals with COVID-19 (5).

310

311 When tested in a mouse model of SARS-CoV-2 lung infection all vaccinated BALB/c mice exhibited
312 little or no replication of SARS-CoV-2, irrespective whether low or high-dose MVA-SARS-2-S was
313 used for vaccination. Particularly encouraging was the complete absence of detectable infectious
314 virus in the lung tissues of immunized animals. Notably, we found no evidence of a potential
315 enhancement of SARS-CoV-2 infection through S-antigen-specific antibody induction, confirming
316 our data with MVA-MERS-S that the S glycoprotein is an important and safe vaccine antigen (18,
317 19).

318 Overall, the MVA-SARS-2-S vector vaccine merits further development and the results presented
319 here provided information for the start of a phase 1 clinical trial on 30 September 2020. To
320 counteract the SARS-CoV-2 pandemic, candidate vaccines are being rapidly investigated in
321 unprecedented numbers, and first front-runner vaccines are obtaining emergency licensing in
322 Europe and the USA in 2020 (37). Yet, there is still much to learn when moving forward in COVID-
323 19 vaccination. We expect that optimized protective immunity to COVID-19 will require vaccine
324 approaches eliciting antiviral SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells in a coordinated
325 manner, together with virus neutralizing antibodies, in various population groups including children,
326 the elderly and individuals with comorbidities.

327

328

329 **Materials and Methods**

330

331 **Cell cultures.** DF-1 cells (ATCC® CRL-12203™) were maintained in VP-SFM medium (Thermo
332 Fisher Scientific, Planegg, Germany), 2% heat-inactivated fetal bovine serum (FBS) (Thermo
333 Fisher Scientific, Planegg, Germany) and 2% L-glutamine (Thermo Fisher Scientific, Planegg,
334 Germany). Primary chicken embryonic fibroblasts (CEF) were prepared from 10 to 11-day-old
335 chicken embryos (SPF eggs, VALO, Cuxhaven, Germany) using recombinant trypsin (Tryple™,
336 Thermo Fisher Scientific, Planegg, Germany) and maintained in VP-SFM medium, 10% FBS and

337 1% L-glutamine. Vero cells (ATCC CCL-81) were maintained in Dulbecco's Modified Eagle's
338 Medium (DMEM), 10% FBS and 1% MEM non-essential amino acid solution (Sigma-Aldrich,
339 Taufkirchen, Germany). Human A549 cells (ATCC® CCL-185™) (LGC standards) were maintained
340 in DMEM with high glucose and 10% FBS. Human HeLa cells (ATCC CCL-2) were maintained in
341 Minimum Essential Medium Eagle (MEM) (Sigma-Aldrich, Taufkirchen, Germany), 7% FBS and
342 1% MEM non-essential amino acid solution. Human HaCat cells (CLS Cell Lines Service GmbH,
343 Eppelheim, Germany) were maintained in DMEM, 10% FBS, 1% MEM non-essential amino acid
344 solution and 1% HEPES solution (Sigma-Aldrich, Taufkirchen, Germany). All cells were cultivated
345 at 37 °C and 5 % CO₂.

346 **Plasmid construction.** The coding sequence of the full-length SARS-CoV-2 S protein (SARS-2-
347 S) was modified *in silico* by introducing silent mutations to remove runs of guanines or cytosines
348 and termination signals of vaccinia virus-specific early transcription. In addition, a C-terminal tag
349 sequence encoding nine amino acids (YPYDVPDYA, aa 98-106(38) from influenza virus
350 hemagglutinin (HAtag) was added. The modified SARS-2-S cDNA was produced by DNA synthesis
351 (Eurofins, Ebersberg, Germany) and cloned into the MVA transfer plasmid pIIIH5red under
352 transcriptional control of the synthetic vaccinia virus early/late promoter PmH5 (22) to obtain the
353 MVA expression plasmid pIIIH5red-SARS-2-S.

354 **Generation of recombinant viruses.** MVA vector viruses were obtained following the established
355 protocols for vaccine development as described in previous studies (17, 21, 39) MVA (clonal isolate
356 MVA-F6-sfMR) was grown on CEF under serum-free conditions and served as a non-recombinant
357 backbone virus to construct MVA vector viruses expressing the SARS-CoV-2 S gene sequences.
358 Briefly, monolayers of 90-95% confluent DF-1 or CEF cells were grown in six-well tissue culture
359 plates (Sarstedt, Nürnberg, Germany), infected with non-recombinant MVA at 0.05 multiplicity of
360 infection (MOI), and transfected with plasmid pIIIH5red-SARS-2-S DNA using X-tremeGENE HP
361 DNA Transfection Reagent (Roche Diagnostics, Penzberg, Germany) according to the manual.
362 Afterwards, cell cultures were collected and recombinant MVA viruses were clonally isolated by

363 serial rounds of plaque purification on DF-1 or CEF cell monolayers monitoring for transient co-
364 production of the red fluorescent marker protein mCherry. To obtain vaccine preparations,
365 recombinant MVA–SARS-2-S were amplified on CEF or DF-1 cell monolayers grown in T175 tissue
366 culture flasks, purified by ultracentrifugation through 36% sucrose and reconstituted to high titre
367 stock preparations in Tris-buffered saline pH 7.4. Plaque-forming units (PFU) were counted to
368 determine viral titres (23).

369 **In vitro characterization of recombinant MVA-SARS-2-S.** Genetic identity and genetic stability
370 of vector viruses was confirmed by polymerase chain reaction (PCR) using viral DNA and detection
371 of S-protein synthesis following serial passage at low MOI. For the latter, 95% confluent DF-1 cells
372 were infected at MOI 0.05, incubated for 48h, harvested and used for reinfection. In total, five
373 rounds of low MOI passage were performed. After the fifth passage, sixty virus isolates were
374 obtained and amplified in 24-well DF-1 cultures for further testing. PCR analysis was performed to
375 confirm genetic stability of viral genomes and MVA- and SARS-2-S-specific immunostaining served
376 to monitor recombinant gene expression. The replicative capacity of recombinant MVA was tested
377 in multi-step-growth experiments on monolayers of DF-1, HaCat, HeLa or A549 cells grown in 6-
378 well-tissue-culture plates. Viruses were inoculated at MOI 0.05, harvested at 0, 4, 8, 24, 48, and
379 72 h after infection, and titrated on CEF monolayers to determine infectivities in cell lysates in PFU.

380 **Western Blot analysis of recombinant protein.** To monitor production of the recombinant SARS-
381 2-S protein, DF-1 cells were infected at MOI 10 with recombinant or non-recombinant MVA or
382 remained uninfected (mock). At indicated time points of infection, cell lysates were prepared from
383 infected cells and stored at –80 °C. Proteins from lysates were separated by electrophoresis in a
384 sodium dodecyl sulfate (SDS)-10% polyacrylamide gel (SDS-PAGE; Bio-Rad, Munich) and
385 subsequently transferred to a nitrocellulose membrane by electroblotting. The blots were blocked
386 in a phosphate buffered saline (PBS) buffer containing 5% Bovine Serum Albumin (BSA) (Sigma-
387 Aldrich, Taufkirchen, Germany) and 0.1% Tween-20 (Sigma-Aldrich, Taufkirchen, Germany) and
388 incubated for 60 min with primary antibody, monoclonal anti-HA-tag antibody (1:8000; HA Tag mAb

389 2-2.2.14, Thermo Fisher Scientific, Planegg, Germany) or COVID-19 patient serum (1:200). Next,
390 membranes were washed with 0.1% Tween-20 in PBS and incubated with anti-mouse or anti-
391 human IgG (1:5000; Agilent Dako, Glostrup, Denmark), conjugated to horseradish peroxidase.
392 Blots were washed and developed using SuperSignal® West Dura Extended Duration substrate
393 (Thermo Fisher Scientific, Planegg, Germany). Chemiluminescence was visualized using the
394 ChemiDoc MP Imaging System (Bio-Rad, Munich, Germany). For use of patient serum ethical
395 approval was granted by the Ethics Committee at the Medical Faculty of LMU Munich (vote 20-225
396 KB) in accordance with the guidelines of the Declaration of Helsinki.

397 **Immunostaining of recombinant SARS-2-S protein.** Vero cells were infected with 0.05 MOI
398 MVA-SARS-2-S or non-recombinant MVA and incubated at 37 °C. After 24 h, cells were fixed with
399 4% paraformaldehyde (PFA) for 10 min on ice, washed two times with PBS, and permeabilized
400 with 0.1% Triton X-100 (Sigma-Aldrich, Taufkirchen, Germany) solution in PBS. Permeabilized cells
401 were probed with a monoclonal antibody against the HA-tag epitope (1:1000; HA Tag mAb 2-
402 2.2.14, Thermo Fisher Scientific, Planegg, Germany) to detect SARS-2-S protein. Non-
403 permeabilized cells were stained with a mouse monoclonal antibody obtained against the S protein
404 of SARS-CoV-1 (SARS-1-S; 1:200; GeneTex) before fixation with PFA. Polyclonal goat anti-mouse
405 secondary antibody (1:1000; Life Technologies, Darmstadt, Germany) was used to visualize S-
406 specific staining by red fluorescence. Nuclei were stained with 1 µg/ml of 4,6-diamidino-2-
407 phenylindole (DAPI) (Sigma-Aldrich, Taufkirchen, Germany) and cells were analyzed using the
408 Keyence BZ-X700 microscope (Keyence, Neu-Isenburg, Germany) with a ×100 objective.

409 **Vaccination experiments in mice.** Female BALB/c mice (6 to 10 week-old) were purchased from
410 Charles River Laboratories (Sulzfeld, Germany). Mice were maintained under specified pathogen-
411 free conditions, had free access to food and water, and were allowed to adapt to the facilities for at
412 least one week before vaccination experiments were performed. All animal experiments were
413 handled in compliance with the European and national regulations for animal experimentation
414 (European Directive 2010/63/EU; Animal Welfare Acts in Germany). Immunizations were

415 performed using intramuscular applications with vaccine suspension containing either 10^7 or 10^8
416 PFU recombinant MVA-SARS2-S, non-recombinant MVA or PBS (mock) into the quadriceps
417 muscle of the left hind leg. Blood was collected on days 0, 18, 35, 56 or 70. Coagulated blood was
418 centrifuged at $1300\times g$ for 5 min in MiniCollect vials (Greiner Bio-One, Alphen aan den Rijn, The
419 Netherlands) to separate serum, which was stored at $-20\text{ }^{\circ}\text{C}$ until further analysis.

420 **Transduction of vaccinated mice with Ad_ACE2-mCherry and challenge infection with**
421 **SARS-CoV-2.** All animal experiments were performed in accordance with Animal Welfare Acts in
422 Germany and were approved by the regional authorities. Vaccinated mice were housed under
423 pathogen-free conditions and underwent intratracheal inoculation with 5×10^8 PFU Adenovirus-
424 ACE2-mCherry (cloned at ViraQuest Inc., North Liberty, IA, USA) under ketamine/xylazine
425 anesthesia. Three days post transduction, mice were infected via the intranasal route with 1.5×10^4
426 tissue culture infectious dose 50 (TCID₅₀) SARS-CoV-2 (BavPat1/2020 isolate, European Virus
427 Archive Global # 026V-03883). Mice were sacrificed 4 days post infection and serum as well as
428 lung tissue samples were taken for analysis of virus loads.

429 **Quantitative real-time reverse transcription PCR to determine SARS-CoV-2 or mCherry RNA.**
430 Tissue samples of immunized and challenged mice were excised from the left lung lobes and
431 homogenized in 1 ml DMEM. SARS-CoV-2 titres in supernatants (in TCID₅₀ per ml) were
432 determined on VeroE6 cells. RNA isolation was performed with the RNeasy minikit (Qiagen)
433 according to the manufacturer's instructions. The RNA amount was measured using the NanoDrop
434 ND-100 spectrophotometer. Total RNA was reverse transcribed and quantified by real-time PCR
435 using the OneStep RT-PCR kit (Qiagen) as described previously(40) with the primer pair upE-Fwd
436 and upE-Rev and the probe upE-Prb on a StepOne high-throughput fast real-time PCR system
437 (ThermoFisher). Additionally, for every tissue sample from transduced and infected mice, evidence
438 for successful ACE2 transduction was determined by real-time RT-PCR for mCherry mRNA with
439 the OneStep RT-PCR kit (Qiagen). All samples for mCherry analysis were evaluated in one RT-

440 PCR run. Quantification was carried out using a standard curve based on 10-fold serial dilutions of
441 appropriate control RNA ranging from 10^2 to 10^5 copies.

442

443

444 **Antigen-specific IgG ELISA.** SARS-2-S-specific serum IgG titres were measured by enzyme-
445 linked immunosorbent assay (ELISA) as described previously(41). Flat bottom 96-well ELISA
446 plates (Nunc MaxiSorp Plates, Thermo Fisher Scientific, Planegg, Germany) were coated with
447 50 ng/well recombinant 2019-nCoV (COVID-19) S protein (Full Length-R683A-R685A-HisTag,
448 ACROBiosystems, Newark, USA) overnight at 4 °C. Plates were washed and then blocked for 1 h
449 at 37 °C with blocking buffer containing 1% BSA (Sigma-Aldrich, Taufkirchen, Germany) and 0.15M
450 sucrose (Sigma-Aldrich, Taufkirchen, Germany) dissolved in PBS. Mouse sera were serially diluted
451 three-fold down the plate in PBS containing 1% BSA (PBS/BSA), starting at a dilution of 1:100.
452 Plates were then incubated for 1 h at 37 °C. After incubating and washing, plates were probed with
453 100 µl/well of goat anti-mouse IgG HRP (1:2000; Agilent Dako, Denmark) diluted in PBS/BSA for
454 1 h at 37 °C. After washing, 100 µl/well of 3',5'-Tetramethylbenzidine (TMB) Liquid Substrate
455 System for ELISA (Sigma-Aldrich, Taufkirchen, Germany) was added until a colour change was
456 observed. The reaction was stopped by adding 100µl/well of Stop Reagent for TMB Substrate
457 (450 nm, Sigma-Aldrich, Taufkirchen, Germany). Absorbance was measured at 450 nm. The
458 absorbance of each serum sample was measured at 450 nm with a 620 nm reference wavelength.
459 ELISA data were normalized using the positive control. The cut-off value for positive mouse serum
460 samples was determined by calculating the mean of the normalized OD 450nm values of the PBS
461 control group sera plus 6 standard deviations (mean + 6 SD).

462 **Surrogate virus neutralization assay (sVNT).** To test for the presence of neutralizing anti-SARS-
463 CoV-2-S serum antibodies we used surrogate virus neutralization test as described before with
464 slight modifications (25). Briefly, 6 ng of SARS-CoV-2 S RBD (Trenzyme) was pre-incubated for 1
465 hour at 37 °C with heat-inactivated test sera at final dilutions between 1:20 to 1:540, as indicated

466 on the graphs. Afterwards, SARS-CoV-2 S RBD-serum mixtures were loaded onto MaxiSorp 96F
467 plates (Nunc) coated with 200 ng/well ACE2 [produced in-house as described in Bosnjak et al.(25)]
468 and blocked with 2% bovine serum albumin/2% mouse serum (Invitrogen) and incubated for
469 additional 1 h at 37 °C. As controls we used SARS-CoV-2-S-RBD pre-incubated only with buffer
470 and non-specific mouse serum (Invitrogen). Plates were extensively washed with phosphate-
471 buffered saline/0.05% Tween-20 (PBST), followed by incubation for 1 h at 37 °C with an HRP-
472 conjugated anti-His-tag antibody (1.2 µg/ml; clone HIS 3D5). After appropriate washing,
473 colorimetric signals were developed by addition of the chromogenic substrate 3,3',5,5'-
474 tetramethylbenzidine (TMB; TMB Substrate Reagent Set, BD Biosciences) and stopped by addition
475 of equal volume of 0.2 M H₂SO₄. The optical density values measured at 450 nm and 570 nm
476 (SpectraMax iD3 microplate reader, Molecular Devices) were used to calculate percentage of
477 inhibition after subtraction of background values as inhibition (%) = (1 - Sample OD value/Average
478 SARS-CoV-2 S RBD OD value) x100. To remove background effects, the mean percentage of
479 inhibition from non-specific mouse serum (Invitrogen) was deducted from sample values and
480 neutralizing anti-SARS-CoV2-S antibodies titres were determined as serum dilution that still had
481 binding reduction > mean + 2 SD of values from sera of vehicle-treated mice.

482 **Plaque reduction neutralization test 50 (PRNT₅₀).** We tested serum samples for their
483 neutralization capacity against SARS-CoV-2 (German isolate; GISAID ID EPI_ISL 406862;
484 European Virus Archive Global #026V-03883) by using a previously described protocol(24). We 2-
485 fold serially diluted heat-inactivated samples in Dulbecco modified Eagle medium supplemented
486 with NaHCO₃, HEPES buffer, penicillin, streptomycin, and 1% foetal bovine serum, starting at a
487 dilution of 1:10 in 50 µL. We then added 50 µL of virus suspension (400 plaque-forming units) to
488 each well and incubated at 37°C for 1 h before placing the mixtures on Vero-E6 cells. After
489 incubation for 1 h, we washed, cells supplemented with medium, and incubated for 8 h. After
490 incubation, we fixed the cells with 4% formaldehyde/phosphate-buffered saline (PBS) and stained
491 the cells with polyclonal rabbit anti-SARS-CoV antibody (Sino Biological,
492 <https://www.sinobiological.com>) and a secondary peroxidase-labeled goat anti-rabbit IgG (Dako,

493 <https://www.agilent.com>). We developed the signal using a precipitate forming 3,3',5,5'-
494 tetramethylbenzidine substrate (True Blue; Kirkegaard and Perry Laboratories,
495 <https://www.seracare.com>) and counted the number of infected cells per well by using an
496 ImmunoSpot Image Analyzer (CTL Europe GmbH, <https://www.immunospot.eu>). The serum
497 neutralization titre is the reciprocal of the highest dilution resulting in an infection reduction of >50%
498 (PRNT₅₀). We considered a titre >20 to be positive.

499 **SARS-CoV-2 virus neutralization test (VNT₁₀₀)**. The neutralizing activity of mouse serum
500 antibodies was investigated based on a previously published protocol (9). Briefly, samples were
501 serially diluted in 96-well plates starting from a 1:16 serum dilution. Samples were incubated for 1
502 h at 37°C together with 100 50% tissue culture infectious doses (TCID₅₀) of SARS-CoV-2
503 (BavPat1/2020 isolate, European Virus Archive Global # 026V-03883). Cytopathic effects (CPE)
504 on VeroE6 cells (ATCC CRL1586) were analyzed 4 days after infection. Neutralization was defined
505 as the absence of CPE compared to virus controls. For each test, a positive control (neutralizing
506 COVID-19 patient plasma) was used in duplicates as an inter-assay neutralization standard. Ethical
507 approval was granted by the Ethics Committee at the Medical Faculty of LMU Munich (vote 20-225
508 KB) in accordance with the guidelines of the Declaration of Helsinki.

509 **Prediction and generation of synthetic SARS-2-S peptides**. The sequence of the SARS-CoV-
510 2 S protein (NCBI ID: QHD43416.1, Uniprot ID: P0DTC2 (SPIKE_SARS2)) served for epitope
511 prediction, and probable CD8+ and CD4+ T cell determinants were examined with the Immune
512 Epitope Database and Analysis Resource (IEDB, <https://www.iedb.org/>). For identification of
513 potential CD8+ T cell determinants, the MHC-I Binding Prediction and MHC-I Processing Prediction
514 tools (42, 43) were used and projections for 9-11mer peptides spanning the entire SARS-2-S
515 protein sequence were obtained. The inputs selected for the search included the Prediction Method
516 'IEDB recommended 2.22', the MHC source species 'Mouse' and the MHC class I alleles H2-K^d,
517 H2-D^d and H2-L^d. The output was restricted to a percentile rank cut-off of 10.0. After lists of peptides
518 were generated, all peptides with an IC₅₀ score of 500nM or less were selected for inclusion in the

519 top 5% list. All the peptides in this list were further analyzed using the MHC-I Processing Prediction
520 tool 'Proteasomal cleavage/TAP transport/MHC class I combined predictor'. All peptides with an
521 IC50 score of 500nM or less and a high total score were chosen and subsequently included in the
522 top peptides list. To confirm that these peptides were potential binders of MHC class I alleles H2-
523 K^d, H2-D^d and H2-L^d, they were further screened for MHC I binding using the RankPep server(44).
524 Peptides that were found to bind to any of the above alleles were selected for synthesis and testing.

525 For the identification of potential CD4+ T cell determinants, the MHC-II Binding Prediction tool (42,
526 43) served to obtain 15mer peptides spanning the entire SARS-2-S protein sequence. The inputs
527 for the analysis included the Prediction Method 'IEDB recommended 2.22', the MHC source
528 species 'Mouse' and the MHC class II alleles H2-IA^d and H2-IE^d. Peptides with percentile rank of
529 10.0 or less and an IC50 score of 1000 nM or less were further tested for MHC class II binding
530 using the RankPep server (44). Peptides bound to any of the above MHC class II alleles were
531 selected for synthesis and testing. All peptides were obtained from Thermo Fisher Scientific
532 (Planegg, Germany) as crude material (<50% purity) at a 1–4 mg scale, dissolved in PBS or DMSO
533 to 2 mg/ml, aliquoted and stored at -20 °C.

534 **T cell analysis by Enzyme-Linked Immunospot (ELISPOT).** At days 8 and 14 post prime or
535 prime-boost vaccination, mice were sacrificed and splenocytes were prepared. Briefly, spleens
536 were passed through a 70 µm strainer (Falcon®, Sigma-Aldrich, Taufkirchen, Germany) and
537 incubated with Red Blood Cell Lysis Buffer (Sigma-Aldrich, Taufkirchen, Germany). Cells were
538 washed and resuspended in RPMI-10 (RPMI 1640 medium containing 10% FBS, 1% Penicillin-
539 Streptomycin, 1% HEPES; Sigma-Aldrich, Taufkirchen, Germany). ELISPOT assay (Mabtech
540 ELISpot kit for mouse IFN-γ, Biozol, Eching, Germany) was performed to measure IFN-γ-producing
541 T cells following the manufacturer's instructions. Briefly, 2x10⁵ splenocytes/100µl were seeded in
542 96-well plates and stimulated with individual peptides (2 µg/mL RPMI-10). Non-stimulated cells and
543 cells stimulated with phorbol myristate acetate (PMA) / ionomycin (Sigma-Aldrich, Taufkirchen,
544 Germany) or vaccinia virus peptide SPGAAGYD (F2(G)₂₆₋₃₄; H-2L^d;(26)) served as controls. After

545 incubation at 37 °C for 48 h, plates were stained according to the manufacturer's instructions. Spots
546 were counted and analyzed by using an automated ELISPOT plate reader and software following
547 the manufacturer's instructions (A.EL.VIS Eli.Scan, A.EL.VIS ELISPOTAnalysis Software,
548 Hannover, Germany).

549 **T cell analysis by Intracellular Cytokine Staining (ICS).** The detailed methods for intracellular
550 cytokine staining (ICS) were described previously(41). Briefly, whole splenocytes were diluted in
551 RPMI-10 and plated onto 96-well-U-bottom plates using 10⁶ cells/well. Cells were stimulated with
552 8 µg/ml S₂₆₉₋₂₇₈ peptide or vaccinia virus peptide F₂₂₆₋₃₄ for analysis of SARS-2-S- or MVA-specific
553 CD8+ T cells. Splenocytes stimulated with PMA (10 ng/ml) plus ionomycin (500 ng/ml) served as
554 positive controls and RPMI alone was used as a negative control. After 2 h at 37 °C, brefeldin A
555 (Biolegend, San Diego, CA, USA) was added according to the manufacturer's instructions and
556 stimulated cells were further maintained for 4 h at 37 °C. After the stimulations, cells were washed
557 with FACS buffer (MACSQuant Running Buffer, Miltenyi Biotec, Bergisch Gladbach, Germany, plus
558 2% FBS) and stained extracellularly with anti-mouse CD3 phycoerythrin (PE)-Cy7 (clone 17A2,
559 1:100, Biolegend), anti-mouse CD4 Brilliant Violet 421 (clone GK1.5, 1:600, Biolegend), anti-mouse
560 CD8α Alexa Fluor 488 (clone 53-6.8, 1:300, Biolegend), and purified CD16/CD32 (Fc block; clone
561 93, 1:500, Biolegend) using 50 µl/well diluted in FACS Buffer for 30 min on ice. After staining and
562 washing, cells were incubated with 100 µl/well of the fixable dead cell viability dye Zombie Aqua
563 (1:800, Biolegend) diluted in PBS for 30 min on ice. Cells were then washed, fixed with 100 µl/well
564 of Fixation Buffer (Biolegend) for 20 min at room temperature, washed again, resuspended in
565 200 µl/well of FACS buffer and stored overnight at 4 °C. Next, cells were permeabilized using
566 Intracellular Staining Permeabilization Wash Buffer (Perm Wash buffer; Biolegend; dilution 1:10),
567 and stained intracellularly in 100 µl/well of anti-mouse IFN-γ (clone XMG1.2, 1:200, Biolegend) plus
568 anti-mouse TNF-α (clone MP6-XT22, 1:200, Biolegend) diluted in Perm Wash buffer for 30 min at
569 room temperature. Thereafter, cells were washed with Perm Wash buffer and resuspended in
570 FACS buffer. Prior to analysis, samples were filtered through a 50 µm nylon mesh (Sefar Pty Ltd.,
571 Huntingwood, NSW, Australia) into 5 ml round bottom FACS tubes (Sarstedt, Nümbrecht,

572 Germany). For each antibody, single colour controls were prepared using OneComp eBeads™
573 Compensation Beads (eBioscience, Thermo Fisher Scientific) and cells for the viability dye Zombie
574 Aqua. Data was acquired by the MACSQuant VYB Flow Analyser (Miltenyi Biotec) and analyzed
575 using FlowJo (FlowJo LLC, BD Life Sciences, Ashland, OR, USA).

576 **Statistical analysis.** Data were prepared using GraphPad Prism version 5 (GraphPad Software
577 Inc., San Diego CA, USA) and expressed as mean ± standard error of the mean (SEM). Data were
578 analyzed by unpaired, two-tailed t-tests to compare two groups and one-way ANOVA to compare
579 three or more groups. $P < 0.05$ was used as the threshold for statistical significance.

580

581 **Acknowledgments**

582

583 We thank Patrizia Bonert, Ursula Klostermeier, Johannes Döring and Axel Groß for expert help in
584 animal studies. We thank Nico Becker, Astrid Herwig, Lennart Kämpfer for help with BSL3 sample
585 preparation and testing. This work was supported by the German Center for Infection Research
586 (DZIF: projects TTU 01.921 to GS and SB, TTU 01.712 to GS), the Federal Ministry of Education
587 and Research (BMBF 01KX2026 to GS and SB, BMBF 01KI20702 to GS and SB, ZOOVAC
588 01KI1718, RAPID 01KI1723G to AV; “NaFoUniMedCovid19“ FKZ: 01KX2021, Project “B-FAST” to
589 RF). Deutsche Forschungsgemeinschaft, (DFG, German Research Foundation) Excellence
590 Strategy EXC 2155 “RESIST” (Project ID39087428 to RF), by DFG grant SFB900-B1
591 (Projektnummer 158989968 to RF) and by funds of the state of Lower Saxony (14-76103-184
592 CORONA-11/20 to RF).

593

594

595

596

597

598 **References**

- 599 1. Coronaviridae Study Group of the International Committee on Taxonomy of
600 Viruses, The species Severe acute respiratory syndrome-related coronavirus:
601 classifying 2019-nCoV and naming it SARS-CoV-2. *Nat. Microbiol.* **5**, 536-544
602 (2020).
- 603 2. G. A. Poland, I. G. Ovsyannikova, R. B. Kennedy, SARS-CoV-2 immunity: review
604 and applications to phase 3 vaccine candidates. *Lancet* **396**, 1595-1606 (2020).
- 605 3. S. H. Hodgson *et al.*, What defines an efficacious COVID-19 vaccine? A review
606 of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-
607 2. *Lancet Infect. Dis.* [https://doi.org/10.1016/S1473-3099\(20\)30773-8](https://doi.org/10.1016/S1473-3099(20)30773-8) (2020).
- 608 4. M. N. Ramasamy *et al.*, Safety and immunogenicity of ChAdOx1 nCoV-19
609 vaccine administered in a prime-boost regimen in young and old adults
610 (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet*
611 [10.1016/s0140-6736\(20\)32466-1](https://doi.org/10.1016/s0140-6736(20)32466-1) (2020).
- 612 5. C. Rydyznski Moderbacher *et al.*, Antigen-Specific Adaptive Immunity to SARS-
613 CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell*
614 **183**, 996-1012.e1019 (2020).
- 615 6. D. Wrapp *et al.*, Cryo-EM structure of the 2019-nCoV spike in the prefusion
616 conformation. *Science* **367**, 1260-1263 (2020).
- 617 7. M. Hoffmann *et al.*, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2
618 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e278
619 (2020).
- 620 8. S. J. Zost *et al.*, Potently neutralizing human antibodies that block SARS-CoV-2
621 receptor binding and protect animals. *Nature* **584**, 443-449 (2020).
- 622 9. C. Kreer *et al.*, Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-
623 Neutralizing Antibodies from COVID-19 Patients. *Cell* **182**, 843-854.e812 (2020).
- 624 10. P. M. Folegatti *et al.*, Safety and immunogenicity of the ChAdOx1 nCoV-19
625 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind,
626 randomised controlled trial. *Lancet* **396**, 467-478 (2020).
- 627 11. L. A. Jackson *et al.*, An mRNA Vaccine against SARS-CoV-2 — Preliminary
628 Report. *N. Engl. J. Med.* **383**, 1920-1931 (2020).

- 629 12. M. J. Mulligan *et al.*, Phase I/II study of COVID-19 RNA vaccine BNT162b1 in
630 adults. *Nature* **586**, 589-593 (2020).
- 631 13. E. E. Walsh *et al.*, Safety and Immunogenicity of Two RNA-Based Covid-19
632 Vaccine Candidates. *N. Engl. J. Med.* 10.1056/NEJMoa2027906 (2020).
- 633 14. G. Sutter, B. Moss, Nonreplicating vaccinia vector efficiently expresses
634 recombinant genes. *Proc. Natl. Acad. Sci. U. S. A.* **89**, 10847-10851 (1992).
- 635 15. A. Volz, G. Sutter, "Chapter Five - Modified Vaccinia Virus Ankara: History, Value
636 in Basic Research, and Current Perspectives for Vaccine Development" in *Adv.*
637 *Virus Res.*, M. Kielian, T. C. Mettenleiter, M. J. Roossinck, Eds. (Academic
638 Press, 2017), vol. 97, pp. 187-243.
- 639 16. F. Chiuppesi *et al.*, Development of a multi-antigenic SARS-CoV-2 vaccine
640 candidate using a synthetic poxvirus platform. *Nat. Commun.* **11**, 6121 (2020).
- 641 17. F. Song *et al.*, Middle East respiratory syndrome coronavirus spike protein
642 delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing
643 antibodies. *J. Virol.* **87**, 11950-11954 (2013).
- 644 18. A. Volz *et al.*, Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara
645 Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein. *J.*
646 *Virol.* **89**, 8651-8656 (2015).
- 647 19. B. L. Haagmans *et al.*, An orthopoxvirus-based vaccine reduces virus excretion
648 after MERS-CoV infection in dromedary camels. *Science* **351**, 77-81 (2016).
- 649 20. S. Veit, S. Jany, R. Fux, G. Sutter, A. Volz, CD8+ T Cells Responding to the
650 Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered
651 by Vaccinia Virus MVA in Mice. *Viruses* **10** (2018).
- 652 21. T. Koch *et al.*, Safety and immunogenicity of a modified vaccinia virus Ankara
653 vector vaccine candidate for Middle East respiratory syndrome: an open-label,
654 phase 1 trial. *Lancet Infect. Dis.* **20**, 827-838 (2020).
- 655 22. L. S. Wyatt, S. T. Shors, B. R. Murphy, B. Moss, Development of a replication-
656 deficient recombinant vaccinia virus vaccine effective against parainfluenza virus
657 3 infection in an animal model. *Vaccine* **14**, 1451-1458 (1996).
- 658 23. M. Kremer *et al.*, Easy and efficient protocols for working with recombinant
659 vaccinia virus MVA. *Methods Mol. Biol.* **890**, 59-92 (2012).

- 660 24. N. M. A. Okba *et al.*, Severe Acute Respiratory Syndrome Coronavirus
661 2-Specific Antibody Responses in Coronavirus Disease Patients. *Emerging*
662 *Infect. Dis* 26(7):1478-1488 **26** (2020).
- 663 25. B. Bošnjak *et al.*, Low serum neutralizing anti-SARS-CoV-2 S antibody levels in
664 mildly affected COVID-19 convalescent patients revealed by two different
665 detection methods. *Cell. Mol. Immunol.* 10.1038/s41423-020-00573-9 (2020).
- 666 26. D. C. Tschärke *et al.*, Poxvirus CD8+ T-Cell Determinants and Cross-Reactivity
667 in BALB/c Mice. *J. Virol.* **80**, 6318-6323 (2006).
- 668 27. J. Sun *et al.*, Generation of a Broadly Useful Model for COVID-19 Pathogenesis,
669 Vaccination, and Treatment. *Cell* **182**, 734-743.e735 (2020).
- 670 28. L.-Y. R. Wong *et al.*, Sensitization of Non-permissive Laboratory Mice to SARS-
671 CoV-2 with a Replication-Deficient Adenovirus Expressing Human ACE2. *STAR*
672 *Protocols* <https://doi.org/10.1016/j.xpro.2020.100169>, 100169 (2020).
- 673 29. J. A. Jaimes, J. K. Millet, G. R. Whittaker, Proteolytic Cleavage of the SARS-
674 CoV-2 Spike Protein and the Role of the Novel S1/S2 Site. *iScience* **23**, 101212
675 (2020).
- 676 30. R. J. G. Hulswit, C. A. M. de Haan, B. J. Bosch, "Chapter Two - Coronavirus
677 Spike Protein and Tropism Changes" in *Adv. Virus Res.*, J. Ziebuhr, Ed.
678 (Academic Press, 2016), vol. 96, pp. 29-57.
- 679 31. L. Grzelak *et al.*, A comparison of four serological assays for detecting anti-
680 SARS-CoV-2 antibodies in human serum samples from different populations. *Sci.*
681 *Transl. Med.* **12**, eabc3103 (2020).
- 682 32. J. Buchrieser *et al.*, Syncytia formation by SARS-CoV-2-infected cells. *EMBO J.*
683 **39**, e106267 (2020).
- 684 33. N. van Doremalen *et al.*, ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2
685 pneumonia in rhesus macaques. *bioRxiv : the preprint server for biology*
686 10.1101/2020.05.13.093195, 2020.2005.2013.093195 (2020).
- 687 34. N. B. Mercado *et al.*, Single-shot Ad26 vaccine protects against SARS-CoV-2 in
688 rhesus macaques. *Nature* **586**, 583-588 (2020).
- 689 35. K. S. Corbett *et al.*, Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2
690 in Nonhuman Primates. *N. Engl. J. Med.* **383**, 1544-1555 (2020).
- 691 36. L. H. Tostanoski *et al.*, Ad26 vaccine protects against SARS-CoV-2 severe
692 clinical disease in hamsters. *Nat. Med.* **26**, 1694-1700 (2020).

- 693 37. F. Krammer, SARS-CoV-2 vaccines in development. *Nature* **586**, 516-527
694 (2020).
- 695 38. I. A. Wilson *et al.*, The structure of an antigenic determinant in a protein. *Cell* **37**,
696 767-778 (1984).
- 697 39. J. H. C. M. Kreijtz *et al.*, Safety and immunogenicity of a modified-vaccinia-virus-
698 Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a
699 clinical trial. *Lancet Infect. Dis.* **14**, 1196-1207 (2014).
- 700 40. V. M. Corman *et al.*, Detection of 2019 novel coronavirus (2019-nCoV) by real-
701 time RT-PCR. *Euro Surveill.* **25** (2020).
- 702 41. G. Kalodimou *et al.*, A Soluble Version of Nipah Virus Glycoprotein G Delivered
703 by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice. *Viruses*
704 **12** (2019).
- 705 42. W. Fleri *et al.*, The Immune Epitope Database and Analysis Resource in Epitope
706 Discovery and Synthetic Vaccine Design. *Front. Immunol.* **8** (2017).
- 707 43. S. K. Dhanda *et al.*, IEDB-AR: immune epitope database-analysis resource in
708 2019. *Nucleic Acids Res.* **47**, W502-w506 (2019).
- 709 44. P. A. Reche, J.-P. Glutting, H. Zhang, E. L. Reinherz, Enhancement to the
710 RANKPEP resource for the prediction of peptide binding to MHC molecules using
711 profiles. *Immunogenetics* **56**, 405-419 (2004).

712

713

Fig. 1






Fig. 1. Construction and virological characterization of MVA-SARS-2-S. **(A)** Schematic diagram of the MVA genome with the major deletion sites I to VI. The site of deletion III was targeted for insertion of the gene sequence encoding the S protein of SARS-CoV-2 isolate Wuhan-HU-1 (SARS-2-S). SARS-2-S was placed under transcriptional control of the vaccinia virus promoter PmH5 within the MVA vector plasmid pIIIH5red-SARS-2-S. Insertion occurred via homologous recombination between MVA DNA sequences (flank-1 and flank-2) adjacent to deletion site III in the MVA genome and copies cloned in the vector plasmid. MVA-SARS-2-S was isolated by plaque purification screening for co-production of the red fluorescent marker protein mCherry. A repetition of short flank-1 derived DNA sequences (del) served to remove the marker gene by intragenomic homologous recombination (marker gene deletion).

Fig. 1



(B) Genetic integrity of MVA-SARS-2-S (MVA-S). PCR analysis of genomic viral DNA confirmed stable insertion of the SARS-2-S sequence into deletion site III of the MVA genome. The precise intragenomic deletion of the marker gene mCherry during plaque purification was revealed by amplification of a PCR product with the expected molecular weight (4.8 kb) from MVA-S genomic DNA compared to the large product amplified from pIIIH5red-SARS-2-S plasmid DNA template (pIII-S). The deletion III site-specific oligonucleotide primers amplified a characteristic 0.762 kb DNA fragment from genomic, non-recombinant MVA DNA.

Fig. 1



(C) Multiple-step growth analysis of recombinant MVA-SARS-2-S (MVA-S) and non-recombinant MVA (MVA). Cells were infected at a multiplicity of infection (MOI) of 0.05 with MVA-S or MVA and collected at the indicated time points. Titration was performed on CEF cells and plaque-forming units (PFU) were determined. MVA-S and MVA could be efficiently amplified on DF-1 but failed to productively grow on cells of human origin (HaCat, HeLa and A549).

Fig. 2






Fig. 2. Synthesis of full-length Spike glycoprotein in MVA-SARS-2-S (MVA-S) infected cells. **(A)** Cells were infected at a multiplicity of infection of 0.5. MVA infected cells served as controls. Paraformaldehyde fixed cells were either permeabilized or non-permeabilized and probed with mouse monoclonal antibodies directed against the HA tag or the S protein of SARS-Cov-1 (SARS-1-S). Polyclonal goat anti-mouse secondary antibody was used for S-specific fluorescent staining (red). Cell nuclei were counterstained with DAPI (blue).

Fig. 2




(B) Chicken embryonic fibroblasts (CEF) and Vero cells were infected with a multiplicity of infection (MOI) of 10 and collected 24 hours post infection (hpi).

Fig. 2



(C) Vero cells were infected with MVA-SARS-2-S (MVA-S) at a MOI of 10 and collected after the indicated time points. Deglycosylation with PNGase F (MVA-Sd) was performed with the sample collected after 24 hpi. Polypeptides in cell lysates were separated by SDS-PAGE and analyzed with a monoclonal antibody against the HA-tag (1:8000) (a, b) or with human serum (1:200)

Fig. 2



(D) Lysates from non-infected (Mock) or non-recombinant MVA infected (MVA) cells were used as controls.

Fig. 3




Fig. 3. Antigen-specific humoral immunity induced by inoculation with recombinant MVA-SARS-2-S (MVA-S). Groups of BALB/c mice (n =7 to 12) were vaccinated in a prime-boost regime (21-day interval) with 10⁷ or 10⁸ PFU of MVA-S via the intra muscular (i.m) route. Mice inoculated with saline (PBS) served as controls. **(A,B)** Sera were collected 18 days after the first immunization (prime) and 14 days after the second immunization (prime-boost) and analyzed for SARS-2-S specific IgG titers by ELISA, and **(C-E)** SARS-CoV-2 neutralizing antibodies by plaque reduction assay (PRNT₅₀), virus neutralization (VNT₁₀₀) or surrogate virus neutralization test (sVNT).

Fig. 4




Fig. 4. Activation of SARS-2-S specific CD8+ T cells after prime-boost immunization with MVA-SARS-2-S. Groups of BALB/c mice (n = 4-6) were immunized twice with 10⁷ or 10⁸ PFU of MVA-SARS-2-S (MVA-S) over a 21-day interval via the i.m. route. Mock immunized mice (PBS) were negative controls. **(A, B, C)** Splenocytes were collected and prepared on day 8 after prime, **(D, E, F)** or prime-boost immunization. Total splenocytes were stimulated with the H2d restricted peptide of the SARS-2-S protein S₂₆₈₋₂₇₆ (S1; GYLQPRFTFL) and were measured by IFN- γ ELISPOT assay and IFN- γ and TNF- α ICS plus FACS analysis. **(A, D)** IFN- γ SFC for stimulated splenocytes measured by ELISPOT assay. **(B, E)** IFN- γ production by CD8 T cells measured by FACS analysis. Graphs show the frequency and absolute number of IFN- γ + CD8+ T cells. **(C, F)** Cytokine profile of S1-specific CD8 T cells. Graphs show the mean frequency of IFN- γ -TNF- α +, IFN- γ +TNF- α + and IFN- γ +TNF- α - cells within the cytokine positive CD8+ T cell compartment. Differences between groups were analyzed by one-way ANOVA and Tukey post-hoc test. Asterisks represent statistically significant differences between two groups. * p < 0.05, ** p < 0.01

Fig. 5




Fig. 5. Protective capacity of MVA-SARS-2-S immunization against SARS-CoV-2 infection in human ACE2-transduced BALB/c mice. Groups of BALB/c mice ($n = 4-6$) were immunized twice with 10^7 or 10^8 PFU of MVA-SARS-2-S (MVA-S) over a 21-day interval via the i.m. route. Mock immunized mice (PBS) served as controls. About two weeks after the last immunization the mice were sensitized with an adenovirus expressing hACE2 and mCherry and infected with SARS-CoV-2 five days after transduction. Four days post challenge the animals were sacrificed and samples were taken for further analysis. **(A)** Lung tissues were harvested to determine SARS-CoV-2 RNA loads by viral genome copies, **(B)** the expression of mCherry by mRNA copies, or **(C)** the amounts of infectious SARS-CoV-2 by TCID₅₀/ml. **(D)** Sera were tested for SARS-CoV-2 neutralizing antibodies by virus neutralization (VNT100). Statistical evaluation was performed with GraphPad Prism for Windows. Statistical significance of differences between groups is indicated as follows: *, $p < 0.05$; ***, $p < 0.001$.